This report provides an overview of the toxicology pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Chemotherapy Induced Nausea and Vomiting, Chemotherapy Induced Neutropenia, Chemotherapy Induced Anemia, Chemotherapy Induced Peripheral Neuropathy and features dormant and discontinued projects.
These key indications are all common side effects of cancer chemotherapy treatment, and result in a substantial reduction in the patient’s quality of life. Chemotherapy induced nausea and vomiting or CINV is nausea and vomiting that results specifically from treatment with chemotherapy drugs. Chemotherapy-induced neutropenia is another very common side effect of cancer treatment. Symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pale appearance, rapid heart rate or palpitations, chest pain dizziness and abdominal pain. Chemotherapy-induced anemia symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pale appearance, rapid heart rate or palpitations, chest pain dizziness, cognitive impairment, loss of sexual desire, inability to perform daily functions and/or depression associated with anemia. Finally, chemotherapy-induced peripheral neuropathy (CIPN) is a further potential side effect of cancer treatment. Symptoms include pain, burning, tingling, constipation, muscle weakness, blood pressure changes and balance problems.
The size of these pipelines ranges from 16 in chemotherapy-induced anemia to 41 in chemotherapy-induced neutropenia and CIPN. In CINV and CIPN, there is a relatively diverse range of targets which are being studied, although most of these targets are neurotransmitter receptors. On the other hand, the pipelines for chemotherapy-induced neutropenia and anemia are far more limited in the range of molecular targets being studied.
– Which companies are the most active within the pipeline for toxicology therapeutics?
– Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
– To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
– What are the most important R&D milestones and data publications to have happened in the field of toxicology therapeutics?
Reasons to buy
– Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
– Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
– Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
– Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Table of Content: Key Points
Executive Summary 3
Table of Contents 4
List of Tables 6
List of Figures 9
Toxicology Cluster Chemotherapy Related Toxicity Report Coverage 10
Chemotherapy Induced Nausea and Vomiting – Overview 10
Chemotherapy Induced Neutropenia – Overview 10
Chemotherapy Induced Anemia – Overview 10
Chemotherapy Induced Peripheral Neuropathy – Overview 10
Therapeutics Development 11
Chemotherapy Induced Nausea and Vomiting 11
Chemotherapy Induced Neutropenia 15
Chemotherapy Induced Anemia 20
Chemotherapy Induced Peripheral Neuropathy 23
Therapeutics Assessment 30
Chemotherapy Induced Nausea and Vomiting 30
Chemotherapy Induced Neutropenia 37
Chemotherapy Induced Anemia 45
Chemotherapy Induced Peripheral Neuropathy 53
Companies Involved in Therapeutics Development 61
Chemotherapy Induced Nausea and Vomiting 61
Chemotherapy Induced Neutropenia 70
Chemotherapy Induced Anemia 82
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Get in touch: